The clinical application of class 1.1 new drugs of shr7390 tablets entered CFDA drug review center on December 31, 2014, and took a special review channel
Shr7390 is a MEK kinase inhibitor developed for cancer
Last week, Hengrui just got 6 clinical approvals
On February 13, 2015, the clinical application of class 1.1 new drug of bgb-3111 capsule entered the CFDA drug review center and took a special review channel
Bgb-3111 is a Btk inhibitor, which is said to have higher selectivity than ibrutinib, the world's first btik inhibitor
The preliminary results of the phase I study of bgb-3111 single drug in the treatment of multiple advanced B-cell malignancies were announced at the ash2015 annual meeting of Baiji Shenzhou on December 7.